MedPath
HSA Approval

APO-TRIAZIDE TABLET

SIN06552P

APO-TRIAZIDE TABLET

APO-TRIAZIDE TABLET

September 11, 1991

PHARMAFORTE SINGAPORE PTE LTD

PHARMAFORTE SINGAPORE PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantPHARMAFORTE SINGAPORE PTE LTD
Licence HolderPHARMAFORTE SINGAPORE PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET

ORAL

Medical Information

C03EA01

hydrochlorothiazide and potassium-sparing agents

Manufacturer Information

PHARMAFORTE SINGAPORE PTE LTD

APOTEX INC

Active Ingredients

HYDROCHLOROTHIAZIDE

25 mg

Hydrochlorothiazide

TRIAMTERENE

50 mg

Triamterene

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

APO-TRIAZIDE TABLET - HSA Approval | MedPath